LA JOLLA, Calif.--(BUSINESS WIRE)--July 26, 2006--Stratagene Corporation (NASDAQ:STGN - News), a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced today that it was informed in the matter of Invitrogen Corporation vs. Stratagene which was heard in the United States District Court for the Western District of Texas, that the jury determined that Invitrogen’s 4,981,797 patent is valid and that Stratagene infringed that patent by making and selling its competent E. coli cell products. The jury decided to award Invitrogen a 15% royalty rate on sales between the years 1997 and 2004 (for a total of $7.8 million in damages) and found Stratagene to have willfully infringed the patent only between the years 1997 and 2001. The jury found that Invitrogen was not entitled to lost profits because Stratagene has had a non-infringing manufacturing process for competent cells. Invitrogen had been seeking $32 million in damages based on a lost profits argument. Stratagene has the option to appeal yesterday’s verdict.
